NasdaqCM - Delayed Quote USD

aTyr Pharma, Inc. (LIFE)

1.6200 +0.0300 (+1.89%)
At close: April 18 at 4:00 PM EDT
1.6500 +0.03 (+1.85%)
After hours: April 18 at 7:59 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Sanjay S. Shukla M.D., M.S. President, CEO & Director 768.18k -- 1972
Ms. Jill M. Broadfoot Chief Financial Officer 544.75k -- 1962
Ms. Nancy E. Denyes Krueger General Counsel & Corporate Secretary 518.2k -- 1968
Xiang-Lei Yang Ph.D. Founder -- -- --
Ms. Ashlee Dunston Director of Investor Relations & Corporate Communications -- -- --
Mr. Peter Villiger Vice President of Corporate Development -- -- --
Ms. Danielle Campbell VP of Human Resource -- -- --
Dr. Leslie Nangle Ph.D. Vice President of Research -- -- --
Dr. Ying J. Buechler Ph.D. Executive Director of Biologics Development & Manufacturing -- -- --
Dr. David J. King Ph.D. Scientific Consultant 327.31k -- 1959

aTyr Pharma, Inc.

10240 Sorrento Valley Road
Suite 300
San Diego, CA 92121
United States
858 731 8389 https://www.atyrpharma.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
56

Description

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Corporate Governance

aTyr Pharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

  • Apr 05, 2024
    DEF 14A: Proxy Statements
    See Full Filing
  • Mar 14, 2024
    8-K: Corporate Changes & Voting Matters
    See Full Filing
  • Jan 18, 2024
    SC 13G/A: Tender Offer/Acquisition Reports
    See Full Filing
  • Nov 16, 2023
    CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
    See Full Filing
  • Nov 09, 2023
    8-K: Corporate Changes & Voting Matters
    See Full Filing

Upcoming Events

May 07, 2024 - May 13, 2024
aTyr Pharma, Inc. Earnings Call

Related Tickers

ABOS Acumen Pharmaceuticals, Inc.
3.1600
-8.93%
 
BOLT Bolt Biotherapeutics, Inc.
1.1400
+2.70%
 
ALGS Aligos Therapeutics, Inc.
0.7931
+0.78%
 
TSBX Turnstone Biologics Corp.
2.7100
+0.74%
 
MDNAF Medicenna Therapeutics Corp.
1.2400
-2.36%
 
IPSC Century Therapeutics, Inc.
2.9750
+4.75%
 
ACET Adicet Bio, Inc.
2.0250
-10.79%
 
CNSP CNS Pharmaceuticals, Inc.
0.2040
-0.24%
 
NXTC NextCure, Inc.
1.5700
+3.97%
 
LRMR Larimar Therapeutics, Inc.
6.38
-9.50%